FDA approves gene-editing treatment for sickle cell disease
The U.S. Food and Drug Administration on Friday approved a landmark gene-editing treatment for sickle cell disease, a painful condition that affects approximately 100,000 people in the United States, predominantly people of color. The innovative therapy promises to repair the gene responsible for the disease. The breakthrough offers a beacon of hope for Johnny Lubin,
Read More